Implications of HIV diversity for the HIV-1 pandemic

Journal of Infection

Volumn 66, Issue 5, 2013, Pages 391-400

  Hemelaar, Joris ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CRF; Diversity; HIV; Recombinant; Subtype; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ANTIVIRAL RESISTANCE; CELLULAR IMMUNITY; CONSENSUS SEQUENCE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENETIC RECOMBINATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; MOLECULAR EPIDEMIOLOGY; MUTATION RATE; NONHUMAN; PANDEMIC; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PLACENTAL TRANSFER; PUBLIC HEALTH PROBLEM; REVERSE TRANSCRIPTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIMIAN IMMUNODEFICIENCY VIRUS; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ZOONOSIS;

GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; PANDEMICS;

EID: 84875598818     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.026     Document Type: Review

References (106)

1. UNAIDS Report on the global AIDS epidemic 2010 2010, UNAIDS, Geneva.
2. Keele B.F., Van Heuverswyn F., Li Y., Bailes E., Takehisa J., Santiago M.L., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313(5786):523-526.
3. Van Heuverswyn F., Li Y., Neel C., Bailes E., Keele B.F., Liu W., et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006, 444(7116):164.
4. Plantier J.C., Leoz M., Dickerson J.E., De Oliveira F., Cordonnier F., Lemee V., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15(8):871-872.
5. Worobey M., Gemmel M., Teuwen D.E., Haselkorn T., Kunstman K., Bunce M., et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455(7213):661-664.
6. Los Alamos National Laboratory. [accessed 31.10.12]. http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html.
7. Liu Y., Li L., Bao Z., Li H., Zhuang D., Liu S., et al. Identification of a novel HIV type 1 circulating recombinant form (CRF52_01B) in Southeast Asia. AIDS Res Hum Retroviruses Apr 5, 2012, [Epub ahead of print].
8. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., et al. HIV-1 nomenclature proposal. Science 2000, 288(5463):55-56.
9. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. WHO-UNAIDS network for HIV isolation and characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25(5):679-689.
10. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
11. Tebit D.M., Arts E.J. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011, 11(1):45-56.
12. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012, 18(3):182-192.
13. Tscherning C., Alaeus A., Fredriksson R., Bjorndal A., Deng H., Littman D.R., et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998, 241(2):181-188.
14. Abebe A., Demissie D., Goudsmit J., Brouwer M., Kuiken C.L., Pollakis G., et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999, 13(11):1305-1311.
15. Esbjornsson J., Mansson F., Martinez-Arias W., Vincic E., Biague A.J., da Silva Z.J., et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa. Retrovirology 2010, 7:23.
16. Arien K.K., Abraha A., Quinones-Mateu M.E., Kestens L., Vanham G., Arts E.J. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005, 79(14):8979-8990.
17. Abraha A., Nankya I.L., Gibson R., Demers K., Tebit D.M., Johnston E., et al. CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. J Virol 2009, 83(11):5592-5605.
18. Rodriguez M.A., Ding M., Ratner D., Chen Y., Tripathy S.P., Kulkarni S.S., et al. High replication fitness and transmission efficiency of HIV-1 subtype C from India: implications for subtype C predominance. Virology 2009, 385(2):416-424.
19. Njai H.F., Gali Y., Vanham G., Clybergh C., Jennes W., Vidal N., et al. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006, 3:40.
20. Lau K.A., Wang B., Miranda-Saksena M., Boadle R., Kamarulzaman A., Ng K.P., et al. Evidence for possible biological advantages of the newly emerging HIV-1 circulating recombinant form from Malaysia - CRF33_01B in comparison to its progenitors - CRF01_AE and subtype B. Curr HIV Res 2010, 8(3):259-271.
21. Yebra G., Rivas P., Herrero M.D., Lopez M., de Mulder M., Puente S., et al. Clinical differences and viral diversity between newly HIV type 1-diagnosed African and non-African patients in Spain (2005-2007). AIDS Res Hum Retroviruses 2009, 25(1):37-44.
22. Bobkov A.F., Kazennova E.V., Selimova L.M., Khanina T.A., Ryabov G.S., Bobkova M.R., et al. Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J Med Virol 2004, 74(2):191-196.
23. Williamson C., Engelbrecht S., Lambrick M., van Rensburg E.J., Wood R., Bredell W., et al. HIV-1 subtypes in different risk groups in South Africa. Lancet Sep 16, 1995, 346(8977):782.
24. Kunanusont C., Foy H.M., Kreiss J.K., Rerks-Ngarm S., Phanuphak P., Raktham S., et al. HIV-1 subtypes and male-to-female transmission in Thailand. Lancet 1995, 345(8957):1078-1083.
25. Kato S., Saito R., Hiraishi Y., Kitamura N., Matsumoto T., Hanabusa H., et al. Differential prevalence of HIV type 1 subtype B and CRF01_AE among different sexual transmission groups in Tokyo, Japan, as revealed by subtype-specific PCR. AIDS Res Hum Retroviruses 2003, 19(11):1057-1063.
26. Herring B.L., Ge Y.C., Wang B., Ratnamohan M., Zheng F., Cunningham A.L., et al. Segregation of human immunodeficiency virus type 1 subtypes by risk factor in Australia. J Clin Microbiol 2003, 41(10):4600-4604.
27. Hughes G.J., Fearnhill E., Dunn D., Lycett S.J., Rambaut A., Leigh Brown A.J., et al. Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog 2009, 5(9):e1000590.
28. Op de Coul E.L., Coutinho R.A., van der Schoot A., van Doornum G.J., Lukashov V.V., Goudsmit J., et al. The impact of immigration on env HIV-1 subtype distribution among heterosexuals in the Netherlands: influx of subtype B and non-B strains. AIDS 2001, 15(17):2277-2286.
29. John-Stewart G.C., Nduati R.W., Rousseau C.M., Mbori-Ngacha D.A., Richardson B.A., Rainwater S., et al. Subtype C is associated with increased vaginal shedding of HIV-1. J Infect Dis 2005, 192(3):492-496.
30. Iversen A.K., Learn G.H., Skinhoj P., Mullins J.I., McMichael A.J., Rambaut A. Preferential detection of HIV subtype C' over subtype A in cervical cells from a dually infected woman. AIDS 2005, 19(9):990-993.
31. Walter B.L., Armitage A.E., Graham S.C., de Oliveira T., Skinhoj P., Jones E.Y., et al. Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility. AIDS 2009, 23(9):1047-1057.
32. Wasi C., Herring B., Raktham S., Vanichseni S., Mastro T.D., Young N.L., et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995, 9(8):843-849.
33. Kiwanuka N., Laeyendecker O., Quinn T.C., Wawer M.J., Shepherd J., Robb M., et al. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS 2009, 23(18):2479-2484.
34. Blackard J.T., Renjifo B., Fawzi W., Hertzmark E., Msamanga G., Mwakagile D., et al. HIV-1 LTR subtype and perinatal transmission. Virology 2001, 287(2):261-265.
35. Renjifo B., Fawzi W., Mwakagile D., Hunter D., Msamanga G., Spiegelman D., et al. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol 2001, 4(1):16-25.
36. Renjifo B., Gilbert P., Chaplin B., Msamanga G., Mwakagile D., Fawzi W., et al. Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 2004, 18(12):1629-1636.
37. Yang C., Li M., Newman R.D., Shi Y.P., Ayisi J., van Eijk A.M., et al. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS 2003, 17(11):1667-1674.
38. Koulinska I.N., Villamor E., Msamanga G., Fawzi W., Blackard J., Renjifo B., et al. Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes. Virus Res 2006, 120(1-2):191-198.
39. Eshleman S.H., Guay L.A., Mwatha A., Brown E., Musoke P., Mmiro F., et al. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV network for prevention trials 012. J Acquir Immune Defic Syndr 2005, 39(5):593-597.
40. Murray M.C., Embree J.E., Ramdahin S.G., Anzala A.O., Njenga S., Plummer F.A. Effect of human immunodeficiency virus (HIV) type 1 viral genotype on mother-to-child transmission of HIV-1. J Infect Dis 2000, 181(2):746-749.
41. Fellay J., Ge D., Shianna K.V., Colombo S., Ledergerber B., Cirulli E.T., et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009, 5(12):e1000791.
42. Hollingsworth T.D., Laeyendecker O., Shirreff G., Donnelly C.A., Serwadda D., Wawer M.J., et al. HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog 2010, 6(5):e1000876.
43. Alizon S., von Wyl V., Stadler T., Kouyos R.D., Yerly S., Hirschel B., et al. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 2010, 6(9):e1001123.
44. Neilson J.R., John G.C., Carr J.K., Lewis P., Kreiss J.K., Jackson S., et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999, 73(5):4393-4403.
45. Fischetti L., Opare-Sem O., Candotti D., Lee H., Allain J.P. Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS 2004, 18(8):1208-1210.
46. Baeten J.M., Chohan B., Lavreys L., Chohan V., McClelland R.S., Certain L., et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007, 195(8):1177-1180.
47. Hu D.J., Vanichseni S., Mastro T.D., Raktham S., Young N.L., Mock P.A., et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001, 15(6):683-691.
48. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000, 355(9210):1131-1137.
49. Deschamps M.M., Fitzgerald D.W., Pape J.W., Johnson W.D. HIV infection in Haiti: natural history and disease progression. AIDS 2000, 14(16):2515-2521.
50. Rangsin R., Piyaraj P., Sirisanthana T., Sirisopana N., Short O., Nelson K.E. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 2007, 21(Suppl. 6):S39-S46.
51. Costello C., Nelson K.E., Suriyanon V., Sennun S., Tovanabutra S., Heilig C.M., et al. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 2005, 34(3):577-584.
52. Nelson K.E., Costello C., Suriyanon V., Sennun S., Duerr A. Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992-2007. AIDS 2007, 21(Suppl. 6):S47-S54.
53. Lavreys L., Baeten J.M., Chohan V., McClelland R.S., Hassan W.M., Richardson B.A., et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006, 42(9):1333-1339.
54. Van der Paal L., Shafer L.A., Todd J., Mayanja B.N., Whitworth J.A., Grosskurth H. HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda. AIDS 2007, 21(Suppl. 6):S21-S29.
55. Morgan D., Mahe C., Mayanja B., Okongo J.M., Lubega R., Whitworth J.A. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. AIDS 2002, 16(4):597-603.
56. Isingo R., Zaba B., Marston M., Ndege M., Mngara J., Mwita W., et al. Survival after HIV infection in the pre-antiretroviral therapy era in a rural Tanzanian cohort. AIDS 2007, 21(Suppl. 6):S5-S13.
57. Peters P.J., Karita E., Kayitenkore K., Meinzen-Derr J., Kim D.J., Tichacek A., et al. HIV-infected Rwandan women have a high frequency of long-term survival. AIDS 2007, 21(Suppl. 6):S31-S37.
58. Glynn J.R., Sonnenberg P., Nelson G., Bester A., Shearer S., Murray J. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 2007, 21(5):625-632.
59. Kaleebu P., French N., Mahe C., Yirrell D., Watera C., Lyagoba F., et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002, 185(9):1244-1250.
60. Kiwanuka N., Laeyendecker O., Robb M., Kigozi G., Arroyo M., McCutchan F., et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008, 197(5):707-713.
61. Lutalo T., Gray R.H., Wawer M., Sewankambo N., Serwadda D., Laeyendecker O., et al. Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda. AIDS 2007, 21(Suppl. 6):S15-S19.
62. Vasan A., Renjifo B., Hertzmark E., Chaplin B., Msamanga G., Essex M., et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006, 42(6):843-852.
63. Kiwanuka N., Robb M., Laeyendecker O., Kigozi G., Wabwire-Mangen F., Makumbi F.E., et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr 2010, 54(2):180-184.
64. Sacktor N., Nakasujja N., Skolasky R.L., Rezapour M., Robertson K., Musisi S., et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009, 49(5):780-786.
65. Rainwater S., DeVange S., Sagar M., Ndinya-Achola J., Mandaliya K., Kreiss J.K., et al. No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses 2005, 21(12):1060-1065.
66. Conroy S.A., Laeyendecker O., Redd A.D., Collinson-Streng A., Kong X., Makumbi F., et al. Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002. AIDS Res Hum Retroviruses 2010, 26(10):1087-1091.
67. Kwon J.A., Yoon S.Y., Lee C.K., Lim C.S., Lee K.N., Sung H.J., et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods 2006, 133(1):20-26.
68. Aghokeng A.F., Mpoudi-Ngole E., Dimodi H., Atem-Tambe A., Tongo M., Butel C., et al. Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS ONE 2009, 4(11):e7702.
69. Rouet F., Foulongne V., Viljoen J., Steegen K., Becquart P., Valea D., et al. Comparison of the generic HIV viral load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods 2010, 163(2):253-257.
70. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006, 19(6):594-606.
71. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005, 2(4):e112.
72. Martinez-Cajas J.L., Pai N.P., Klein M.B., Wainberg M.A. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009, 12(1):11.
73. Depatureaux A., Charpentier C., Leoz M., Unal G., Damond F., Kfutwah A., et al. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr 2011, 56(2):139-145.
74. Trono D., Van Lint C., Rouzioux C., Verdin E., Barre-Sinoussi F., Chun T.W., et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329(5988):174-180.
75. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10(1):11-23.
76. Goulder P.J., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412(6844):334-338.
77. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004, 10(3):282-289.
78. Kawashima Y., Pfafferott K., Frater J., Matthews P., Payne R., Addo M., et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009, 458(7238):641-645.
79. Bunnik E.M., Euler Z., Welkers M.R., Boeser-Nunnink B.D., Grijsen M.L., Prins J.M., et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med 2010, 16(9):995-997.
80. Alter G., Heckerman D., Schneidewind A., Fadda L., Kadie C.M., Carlson J.M., et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011, 476(7358):96-100.
81. Arien K.K., Vanham G., Arts E.J. Is HIV-1 evolving to a less virulent form in humans?. Nat Rev Microbiol 2007, 5(2):141-151.
82. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482(7383):89-93.
83. Piantadosi A., Chohan B., Chohan V., McClelland R.S., Overbaugh J. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog 2007, 3(11):e177.
84. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
85. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10(8):806-810.
86. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
87. Moore P.L., Ranchobe N., Lambson B.E., Gray E.S., Cave E., Abrahams M.R., et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009, 5(9):e1000598.
88. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009, 5(9):e1000594.
89. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Olivera T.Y., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333(6049):1633-1637.
90. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480(7377):336-343.
91. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194(12):1661-1671.
92. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366(14):1275-1286.
93. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296(5577):2354-2360.
94. Goonetilleke N., Liu M.K., Salazar-Gonzalez J.F., Ferrari G., Giorgi E., Ganusov V.V., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206(6):1253-1272.
95. Tenzer S., Wee E., Burgevin A., Stewart-Jones G., Friis L., Lamberth K., et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009, 10(6):636-646.
96. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
97. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17(3):366-371.
98. Lee J.K., Stewart-Jones G., Dong T., Harlos K., Di Gleria K., Dorrell L., et al. T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med 2004, 200(11):1455-1466.
99. McMichael A., Mwau M., Hanke T. HIV T cell vaccines, the importance of clades. Vaccine 2002, 20(15):1918-1921.
100. Ranasinghe S.R., Kramer H.B., Wright C., Kessler B.M., di Gleria K., Zhang Y., et al. The antiviral efficacy of HIV-specific CD8 T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PLoS Pathog 2011, 7(5):e1001341.
101. Currier J.R., Dowling W.E., Wasunna K.M., Alam U., Mason C.J., Robb M.L., et al. Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans. AIDS 2003, 17(15):2149-2157.
102. Cao H., Mani I., Vincent R., Mugerwa R., Mugyenyi P., Kanki P., et al. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis 2000, 182(5):1350-1356.
103. Goulder P.J., Watkins D.I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008, 8(8):619-630.
104. Nickle D.C., Jensen M.A., Gottlieb G.S., Shriner D., Learn G.H., Rodrigo A.G., et al. Consensus and ancestral state HIV vaccines. Science 2003, 299(5612):1515-1518. author reply 1515-8.
105. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16(3):319-323.
106. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16(3):324-328.